Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter

McCluskey, Anthony G and Mairs, Robert J and Tesson, Mathias and Pimlott, Sally L and Babich, John W and Gaze, Mark N and Champion, Sue and Boyd, Marie (2012) Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. The Journal of Nuclear Medicine, 53 (7). pp. 1146-1154. ISSN 0161-5505 (https://doi.org/10.2967/jnumed.111.095943)

[thumbnail of McCluskey_et_al_2012_Article_JNM_2_.pdf]
Preview
 PDF. Filename: McCluskey_et_al_2012_Article_JNM_2_.pdf
Preprint
Download (297kB)| Preview

Abstract

Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA damage and supra-additive toxicity to NAT-expressing cells and xenografts. This combination treatment is undergoing clinical evaluation. This present study investigated the potential of PARP-1 inhibition, in vitro and in vivo, to further enhance [131I]MIBG/topotecan efficacy.

CORE (COnnecting REpositories)